Invesco
NRIX icon

Invesco’s Nurix Therapeutics NRIX Stock Holding History

Invesco’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.32M Sell
178,049
-25,560
-13% -$435K ﹤0.01% 2277
2026
Q1 		$3.16M Sell
203,609
-140,221
-41% -$2.33M ﹤0.01% 2359
2025
Q4 		$6.52M Buy
343,830
+183,909
+115% +$2.64M ﹤0.01% 2103
2025
Q3 		$1.48M Buy
159,921
+22,650
+17% +$235K ﹤0.01% 2746
2025
Q2 		$1.56M Buy
137,271
+19,636
+17% +$212K ﹤0.01% 2667
2025
Q1 		$1.4M Buy
117,635
+65,655
+126% +$1.1M ﹤0.01% 2690
2024
Q4 		$979K Sell
51,980
-361,360
-87% -$8.28M ﹤0.01% 2925
2024
Q3 		$9.29M Buy
413,340
+48,042
+13% +$1.09M ﹤0.01% 1884
2024
Q2 		$7.62M Buy
365,298
+52,388
+17% +$816K ﹤0.01% 1961
2024
Q1 		$4.6M Buy
312,910
+262,085
+516% +$2.82M ﹤0.01% 2290
2023
Q4 		$525K Buy
50,825
+3,421
+7% +$23.4K ﹤0.01% 3185
2023
Q3 		$373K Sell
47,404
-328
-0.7% -$3K ﹤0.01% 3348
2023
Q2 		$477K Sell
47,732
-702
-1% -$7.16K ﹤0.01% 3269
2023
Q1 		$430K Buy
48,434
+33,186
+218% +$346K ﹤0.01% 3345
2022
Q4 		$167K Sell
15,248
-30
-0.2% -$362 ﹤0.01% 3739
2022
Q3 		$199K Buy
15,278
+1,981
+15% +$31.4K ﹤0.01% 3684
2022
Q2 		$168K Sell
13,297
-52
-0.4% -$589 ﹤0.01% 3775
2022
Q1 		$187K Buy
13,349
+178
+1% +$3.16K ﹤0.01% 3782
2021
Q4 		$382K Sell
13,171
-2,853
-18% -$86.5K ﹤0.01% 3503
2021
Q3 		$480K Buy
16,024
+2,540
+19% +$78.4K ﹤0.01% 3448
2021
Q2 		$358K Buy
+13,484
New +$396K ﹤0.01% 3558

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco's NRIX Position: Q2 2026 in Review

Invesco reduced its Nurix Therapeutics (NRIX) stake by 13% in Q2 2026, selling an estimated $435K and leaving 178,049 shares worth $4.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

Invesco first reported a position in NRIX in Q2 2021 and has held it in 21 quarters since. The position peaked at $9.29M in Q3 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Invesco held 178,049 shares of Nurix Therapeutics worth $4.32M as of Q2 2026.
  • Invesco sold 25,560 Nurix Therapeutics shares in Q2 2026, an estimated $435K.
  • Nurix Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2277 holding.
  • Invesco first reported a position in Nurix Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Invesco's Nurix Therapeutics position peaked at $9.29M in Q3 2024.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.